Why ERNA, RDW, BRUN Led Gains After EPS Estimate Revisions

ERNA surged 62.7% from $7.53 to $12.25 after the EPS screener detected a forward EPS growth estimate of 87.4% on May 10, suggesting accelerating growth prospects for the biotech firm.

While the 87.4% EPS growth estimate is aggressive, the absence of recent earnings catalysts warrants caution; investors should wait for confirmed clinical or regulatory milestones before entering.

ERNA's 62.7% gain followed an EPS estimate revision detected by the screener on May 10, pointing to bullish analyst sentiment on the company's therapeutic pipeline without disclosed near-term catalysts.

RDW climbed 56.7% from $8.91 to $13.96 after its forward EPS growth estimate was revised upward from 27.0% to 28.5% on May 7, confirmed by Q1 results showing record contract backlog.

With EPS growth revised to 28.5% and record backlog supporting future revenue, RDW shows fundamental momentum; however, the 56.7% run warrants monitoring for a pullback before adding positions.

Redwire's EPS revision to 28.5% on May 7, backed by Q1 2026 earnings showing record contract backlog and significant gross margin improvement, triggered the 56.7% price surge through mid-May.

BRUN climbed 45.7% from $17.69 to $25.77 following its Nasdaq debut on May 11 with $940M in contracted revenue and an EPS growth estimate of 627.3%, reflecting massive anticipated scalability.

The 627.3% EPS growth estimate is exceptionally high and reflects early-stage scalability; investors should evaluate contracted revenue conversion rates and free cash flow generation before committing.

The screener detected a 627.3% forward EPS growth estimate for BRUN as of May 12, driven by $940M in long-term contracted revenue and an expected $375M annualized recurring revenue run rate by FY2026.

AGL surged 45.6% from $59.61 to $86.80 after the EPS screener detected a 27.3% forward EPS growth estimate on May 11, as investors rotated into value-based care platforms with scaled earnings visibility.

Agilon's 27.3% EPS growth estimate and 45.6% run reflect solid momentum in value-based care; the valuation should be assessed against peer multiples before adding exposure at current levels.

AGL's 45.6% gain followed an EPS revision to 27.3% growth detected on May 11, with investors gravitating toward healthcare services firms offering predictable earnings in the scaled value-based care model.

LQDA gained 34.7% from $42.30 to $56.97 after its forward EPS estimate was raised from 92.2% to 95.5% on May 10, validated by Q1 earnings showing $0.52 adjusted EPS vs $0.37 expected and $132.9M revenue.

With YUTREPIA exceeding $500M annualized revenue run rate and 95.5% EPS growth estimate, LQDA shows a self-funded growth model; however, the 34.7% surge calls for assessing valuation against pipeline optionality.

Liquidia's Q1 2026 earnings beat drove the EPS revision to 95.5% on May 10, with YUTREPIA capturing all category growth and the company reaching three consecutive profitable quarters.